Product Information
ZUMANDIMINE 3 MG-0.03 MG TAB is a generic product labeled by Aurobindo Pharma Limited, priced at $0.1511 per EA under NDC 59651003028. Its NADAC has been published 202 times since Nov 23, 2022.
FDA first approved this application on Mar 26, 2018. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Manufacturer
Aurobindo Pharma LimitedNDC
59651003028
Classification
Generic
Dosage Form
KIT
Effective Date
9/23/2026
Approval Type
Generic (ANDA)
FDA Application
ANDA209407FDA Approved
3/26/2018
TE Code
AB
On Market Since
3/26/2018
Price Statistics
The NADAC for ZUMANDIMINE 3 MG-0.03 MG TAB has been published 202 times since Nov 23, 2022, and over the history we have for it it has declined 21.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1511 per EA |
|---|---|
| All-time high | $0.2062 (Apr 12, 2023) |
| All-time low | $0.1445 (Jul 22, 2026) |
| 52-week high | $0.1731 |
| 52-week low | $0.1445 |
| Median price | $0.1731 |
| Average price | $0.1749 |
| Largest weekly change | +27.6% (Jun 19, 2024) |
| Weeks tracked | 202 |
| Tracking since | Nov 23, 2022 |
Generic Alternatives
The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Aurobindo Pharma Limited manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Drospirenone and Ethinyl Estradiol market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ZUMANDIMINE 3 MG-0.03 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for ZUMANDIMINE 3 MG-0.03 MG TAB, manufactured by Aurobindo Pharma Limited, is $0.1511 per EA (NDC 59651003028), effective Sep 30, 2026.
How has the price of ZUMANDIMINE 3 MG-0.03 MG TAB changed over time?
Over the history we have for it, the NADAC for ZUMANDIMINE 3 MG-0.03 MG TAB has declined 21.9%. It has been tracked across 202 weekly CMS publications since Nov 23, 2022.
What are the highest and lowest recorded NADAC prices for ZUMANDIMINE 3 MG-0.03 MG TAB?
Since Nov 23, 2022, the NADAC for ZUMANDIMINE 3 MG-0.03 MG TAB has ranged from a low of $0.1445 (Jul 22, 2026) to a high of $0.2062 (Apr 12, 2023), with a median of $0.1731 per EA.
Are there cheaper alternatives to ZUMANDIMINE 3 MG-0.03 MG TAB?
6 manufacturers publish a NADAC-priced product with the same active ingredient and strength as ZUMANDIMINE 3 MG-0.03 MG TAB in a comparable dosage form, but none are currently priced below it.
Who manufactures ZUMANDIMINE 3 MG-0.03 MG TAB?
ZUMANDIMINE 3 MG-0.03 MG TAB (NDC 59651003028) is labeled by Aurobindo Pharma Limited, and CMS classifies it as a generic product.